Aravive Inc (FRA:VE11)
€ 0.0325 0 (0%) Market Cap: 2.72 Mil Enterprise Value: -2.92 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Aravive Inc at Piper Sandler Healthcare Conference Transcript

Nov 30, 2022 / 08:30PM GMT
Release Date Price: €1.29 (-4.46%)
Ted Tenthoff
Piper Sandler Companies - Analyst

My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. Before I begin, I'm required to draw your attention to certain disclosures regarding the relationship between Piper and Aravive that are posted at the back of the room and also at the registration desk.

Aravive is developing batiraxcept, a high affinity GAS6 decoy receptor. The company is conducting a Phase 3 trial with paclitaxel in ovarian cancer with topline data next year, and also Phase 2 combo studies with Cabometyx in kidney cancer and with gem-Abraxane in pancreatic cancer.

Here to present from the company is Aravive's CEO, Gail McIntyre.

Gail McIntyre
Aravive, Inc. - CEO & Board Director

Thank you, Ted. Thanks for inviting us. I will be making forward-looking statements. So, the typical cautions apply here. As Ted said, we have a lead program called batiraxcept and it is in late-stage clinical trials. We are very different than other companies in that we are the only company targeting GAS6. GAS6 is the sole

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot